MedTrace Logo

A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

NCT07180862 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-01-06

No results posted yet for this study

Summary

Comparing the PK similarity of BAT3306 and Keytruda; in NSCLC participants who were completely removed by surgery as an auxiliary treatment

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

BAT3306

One vial of 4 mL of concentrate contains 100 mg of BAT3306

DRUG

US-Keytruda®

One vial of 4 mL of concentrate contains 100 mg of pembrolizumab

Sponsors & Collaborators

Principal Investigators

  • Xiaorong Dong, Dr. · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-14
Primary Completion
2027-02-28
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07180862 on ClinicalTrials.gov